Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Sell
41
KNSA Quote, Financials, Valuation and Earnings
Last price:
$20.30
Seasonality move
:
-9.83%
Day range:
$20.20 - $20.69
52-week range:
$16.56 - $28.15
Dividend yield:
0%
P/E ratio:
153.73x
P/S ratio:
3.90x
P/B ratio:
3.40x
Volume:
592.6K
Avg. volume:
291.8K
1-year change:
15.41%
Market cap:
$1.5B
Revenue:
$270.3M
EPS (TTM):
-$0.14
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
KNSA
Kiniksa Pharmaceuticals International PLC
|
$111.6M | $0.07 | 47.73% | -25.71% | -- |
|
IBIO
iBio
|
-- | -$0.46 | -100% | -89.82% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$2.6M | -$0.31 | -60.77% | -99.16% | -- |
|
PFE
Pfizer
|
$14.9B | $0.61 | 27.51% | 12.4% | $31.86 |
|
PTN
Palatin Technologies
|
-- | -$0.51 | -100% | -25% | -- |
|
VNDA
Vanda Pharmaceuticals
|
$49.2M | -- | 15.41% | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
KNSA
Kiniksa Pharmaceuticals International PLC
|
$20.59 | -- | $1.5B | 153.73x | $0.00 | 0% | 3.90x |
|
IBIO
iBio
|
$2.48 | -- | $22.7M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$0.53 | -- | $2.6M | -- | $0.00 | 0% | 0.06x |
|
PFE
Pfizer
|
$26.36 | $31.86 | $149.4B | 35.62x | $0.42 | 6.37% | 2.52x |
|
PTN
Palatin Technologies
|
$0.97 | -- | $18.9M | -- | $0.00 | 0% | -- |
|
VNDA
Vanda Pharmaceuticals
|
$4.78 | -- | $278.4M | -- | $0.00 | 0% | 1.45x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
KNSA
Kiniksa Pharmaceuticals International PLC
|
-- | 0.870 | -- | 2.59x |
|
IBIO
iBio
|
4.41% | 6.097 | 5.41% | 3.89x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | 0.704 | 1.51% | 0.75x |
|
PFE
Pfizer
|
41.92% | 0.516 | 40.56% | 0.64x |
|
PTN
Palatin Technologies
|
-- | -0.872 | -- | 0.99x |
|
VNDA
Vanda Pharmaceuticals
|
-- | 0.761 | -- | 4.70x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
KNSA
Kiniksa Pharmaceuticals International PLC
|
$62.8M | -$9.7M | -2.11% | -2.11% | -8.61% | -$2.2M |
|
IBIO
iBio
|
-- | -$4.1M | -90.99% | -148.3% | -1820.57% | -$3.7M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$1.1M | -334.47% | -461.38% | -44% | -$2.1M |
|
PFE
Pfizer
|
$12.4B | $5.3B | 2.66% | 4.63% | 31.06% | $6.1B |
|
PTN
Palatin Technologies
|
$350K | -$7.8M | -- | -- | -2356.3% | -$7M |
|
VNDA
Vanda Pharmaceuticals
|
$45.1M | -$11M | -3.02% | -3.02% | -23.09% | -$14.7M |
Kiniksa Pharmaceuticals International PLC vs. Competitors
-
Which has Higher Returns KNSA or IBIO?
iBio has a net margin of -11.31% compared to Kiniksa Pharmaceuticals International PLC's net margin of -4444.57%. Kiniksa Pharmaceuticals International PLC's return on equity of -2.11% beat iBio's return on equity of -148.3%.
Company Gross Margin Earnings Per Share Invested Capital KNSAKiniksa Pharmaceuticals International PLC55.96% -$0.18 $437M IBIOiBio-- -$0.46 $22.3M -
What do Analysts Say About KNSA or IBIO?
Kiniksa Pharmaceuticals International PLC has a consensus price target of --, signalling upside risk potential of 74.84%. On the other hand iBio has an analysts' consensus of -- which suggests that it could grow by 45.16%. Given that Kiniksa Pharmaceuticals International PLC has higher upside potential than iBio, analysts believe Kiniksa Pharmaceuticals International PLC is more attractive than iBio.
Company Buy Ratings Hold Ratings Sell Ratings KNSAKiniksa Pharmaceuticals International PLC3 0 0 IBIOiBio0 0 0 -
Is KNSA or IBIO More Risky?
Kiniksa Pharmaceuticals International PLC has a beta of 0.268, which suggesting that the stock is 73.21% less volatile than S&P 500. In comparison iBio has a beta of -3.237, suggesting its less volatile than the S&P 500 by 423.713%.
-
Which is a Better Dividend Stock KNSA or IBIO?
Kiniksa Pharmaceuticals International PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kiniksa Pharmaceuticals International PLC pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KNSA or IBIO?
Kiniksa Pharmaceuticals International PLC quarterly revenues are $112.2M, which are larger than iBio quarterly revenues of $175K. Kiniksa Pharmaceuticals International PLC's net income of -$12.7M is lower than iBio's net income of -$4M. Notably, Kiniksa Pharmaceuticals International PLC's price-to-earnings ratio is 153.73x while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kiniksa Pharmaceuticals International PLC is 3.90x versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KNSAKiniksa Pharmaceuticals International PLC3.90x 153.73x $112.2M -$12.7M IBIOiBio-- -- $175K -$4M
-
Which has Higher Returns KNSA or NBY?
NovaBay Pharmaceuticals has a net margin of -11.31% compared to Kiniksa Pharmaceuticals International PLC's net margin of -49.65%. Kiniksa Pharmaceuticals International PLC's return on equity of -2.11% beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital KNSAKiniksa Pharmaceuticals International PLC55.96% -$0.18 $437M NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M -
What do Analysts Say About KNSA or NBY?
Kiniksa Pharmaceuticals International PLC has a consensus price target of --, signalling upside risk potential of 74.84%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 602.96%. Given that NovaBay Pharmaceuticals has higher upside potential than Kiniksa Pharmaceuticals International PLC, analysts believe NovaBay Pharmaceuticals is more attractive than Kiniksa Pharmaceuticals International PLC.
Company Buy Ratings Hold Ratings Sell Ratings KNSAKiniksa Pharmaceuticals International PLC3 0 0 NBYNovaBay Pharmaceuticals0 0 0 -
Is KNSA or NBY More Risky?
Kiniksa Pharmaceuticals International PLC has a beta of 0.268, which suggesting that the stock is 73.21% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.
-
Which is a Better Dividend Stock KNSA or NBY?
Kiniksa Pharmaceuticals International PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kiniksa Pharmaceuticals International PLC pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KNSA or NBY?
Kiniksa Pharmaceuticals International PLC quarterly revenues are $112.2M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Kiniksa Pharmaceuticals International PLC's net income of -$12.7M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Kiniksa Pharmaceuticals International PLC's price-to-earnings ratio is 153.73x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kiniksa Pharmaceuticals International PLC is 3.90x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KNSAKiniksa Pharmaceuticals International PLC3.90x 153.73x $112.2M -$12.7M NBYNovaBay Pharmaceuticals0.06x -- $2.4M -$1.2M
-
Which has Higher Returns KNSA or PFE?
Pfizer has a net margin of -11.31% compared to Kiniksa Pharmaceuticals International PLC's net margin of 25.23%. Kiniksa Pharmaceuticals International PLC's return on equity of -2.11% beat Pfizer's return on equity of 4.63%.
Company Gross Margin Earnings Per Share Invested Capital KNSAKiniksa Pharmaceuticals International PLC55.96% -$0.18 $437M PFEPfizer70.27% $0.78 $159.2B -
What do Analysts Say About KNSA or PFE?
Kiniksa Pharmaceuticals International PLC has a consensus price target of --, signalling upside risk potential of 74.84%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 20.88%. Given that Kiniksa Pharmaceuticals International PLC has higher upside potential than Pfizer, analysts believe Kiniksa Pharmaceuticals International PLC is more attractive than Pfizer.
Company Buy Ratings Hold Ratings Sell Ratings KNSAKiniksa Pharmaceuticals International PLC3 0 0 PFEPfizer8 13 1 -
Is KNSA or PFE More Risky?
Kiniksa Pharmaceuticals International PLC has a beta of 0.268, which suggesting that the stock is 73.21% less volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.
-
Which is a Better Dividend Stock KNSA or PFE?
Kiniksa Pharmaceuticals International PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.37% to investors and pays a quarterly dividend of $0.42 per share. Kiniksa Pharmaceuticals International PLC pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.
-
Which has Better Financial Ratios KNSA or PFE?
Kiniksa Pharmaceuticals International PLC quarterly revenues are $112.2M, which are smaller than Pfizer quarterly revenues of $17.7B. Kiniksa Pharmaceuticals International PLC's net income of -$12.7M is lower than Pfizer's net income of $4.5B. Notably, Kiniksa Pharmaceuticals International PLC's price-to-earnings ratio is 153.73x while Pfizer's PE ratio is 35.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kiniksa Pharmaceuticals International PLC is 3.90x versus 2.52x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KNSAKiniksa Pharmaceuticals International PLC3.90x 153.73x $112.2M -$12.7M PFEPfizer2.52x 35.62x $17.7B $4.5B
-
Which has Higher Returns KNSA or PTN?
Palatin Technologies has a net margin of -11.31% compared to Kiniksa Pharmaceuticals International PLC's net margin of -2357.27%. Kiniksa Pharmaceuticals International PLC's return on equity of -2.11% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital KNSAKiniksa Pharmaceuticals International PLC55.96% -$0.18 $437M PTNPalatin Technologies-- -$0.39 -$111.5K -
What do Analysts Say About KNSA or PTN?
Kiniksa Pharmaceuticals International PLC has a consensus price target of --, signalling upside risk potential of 74.84%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1656.38%. Given that Palatin Technologies has higher upside potential than Kiniksa Pharmaceuticals International PLC, analysts believe Palatin Technologies is more attractive than Kiniksa Pharmaceuticals International PLC.
Company Buy Ratings Hold Ratings Sell Ratings KNSAKiniksa Pharmaceuticals International PLC3 0 0 PTNPalatin Technologies0 0 0 -
Is KNSA or PTN More Risky?
Kiniksa Pharmaceuticals International PLC has a beta of 0.268, which suggesting that the stock is 73.21% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.
-
Which is a Better Dividend Stock KNSA or PTN?
Kiniksa Pharmaceuticals International PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kiniksa Pharmaceuticals International PLC pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KNSA or PTN?
Kiniksa Pharmaceuticals International PLC quarterly revenues are $112.2M, which are larger than Palatin Technologies quarterly revenues of $350K. Kiniksa Pharmaceuticals International PLC's net income of -$12.7M is lower than Palatin Technologies's net income of -$7.8M. Notably, Kiniksa Pharmaceuticals International PLC's price-to-earnings ratio is 153.73x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kiniksa Pharmaceuticals International PLC is 3.90x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KNSAKiniksa Pharmaceuticals International PLC3.90x 153.73x $112.2M -$12.7M PTNPalatin Technologies-- -- $350K -$7.8M
-
Which has Higher Returns KNSA or VNDA?
Vanda Pharmaceuticals has a net margin of -11.31% compared to Kiniksa Pharmaceuticals International PLC's net margin of -11.17%. Kiniksa Pharmaceuticals International PLC's return on equity of -2.11% beat Vanda Pharmaceuticals's return on equity of -3.02%.
Company Gross Margin Earnings Per Share Invested Capital KNSAKiniksa Pharmaceuticals International PLC55.96% -$0.18 $437M VNDAVanda Pharmaceuticals94.65% -$0.09 $541.2M -
What do Analysts Say About KNSA or VNDA?
Kiniksa Pharmaceuticals International PLC has a consensus price target of --, signalling upside risk potential of 74.84%. On the other hand Vanda Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 118.38%. Given that Vanda Pharmaceuticals has higher upside potential than Kiniksa Pharmaceuticals International PLC, analysts believe Vanda Pharmaceuticals is more attractive than Kiniksa Pharmaceuticals International PLC.
Company Buy Ratings Hold Ratings Sell Ratings KNSAKiniksa Pharmaceuticals International PLC3 0 0 VNDAVanda Pharmaceuticals0 0 0 -
Is KNSA or VNDA More Risky?
Kiniksa Pharmaceuticals International PLC has a beta of 0.268, which suggesting that the stock is 73.21% less volatile than S&P 500. In comparison Vanda Pharmaceuticals has a beta of 0.757, suggesting its less volatile than the S&P 500 by 24.283%.
-
Which is a Better Dividend Stock KNSA or VNDA?
Kiniksa Pharmaceuticals International PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kiniksa Pharmaceuticals International PLC pays -- of its earnings as a dividend. Vanda Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KNSA or VNDA?
Kiniksa Pharmaceuticals International PLC quarterly revenues are $112.2M, which are larger than Vanda Pharmaceuticals quarterly revenues of $47.7M. Kiniksa Pharmaceuticals International PLC's net income of -$12.7M is lower than Vanda Pharmaceuticals's net income of -$5.3M. Notably, Kiniksa Pharmaceuticals International PLC's price-to-earnings ratio is 153.73x while Vanda Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kiniksa Pharmaceuticals International PLC is 3.90x versus 1.45x for Vanda Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KNSAKiniksa Pharmaceuticals International PLC3.90x 153.73x $112.2M -$12.7M VNDAVanda Pharmaceuticals1.45x -- $47.7M -$5.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 3.65% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 4.9% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 4.4% over the past day.
